Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2188 - Reduction of blood total lymphocyte count after neoadjuvant treatment is correlated with good tumor regression—results from a prospective randomized control trial


08 Oct 2016


Poster Display


Zehua Wu


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


Z. Wu, Y. Deng, J. Zhang, Y. Cai, H. Hu, L. Yang

Author affiliations

  • Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, 510655 - Guangzhou/CN


Abstract 2188


Blood total lymphocyte count (TLC) before treatment had been reported to be play an important role in tumor immune response. The study aimed to evaluate whether the change of TLC was correlate with tumor regression grade (TRG) after neoadjuvant treatment in locally advanced rectal cancer patients.


TLC before and after neoadjuvant therapy were collected from available 307 patients in FOWARC study. The ratio of TLC reduction after neoadjuvant therapy was calculated. TRG 0-1 was defined as good responder. The correlation between TRG and the ratio of lymphocyte reduction was evaluated.


Of the 307 patients, 153 patients were good responder (TRG 0-1), and 154 had poor response (TRG 2-3). The base-line TLC before neoadjuvant therapy have no significant difference (p = 0.296) between good and poor responders. After neoadjuvant therapy, 85% of patients experienced TLC reduction. TLC after neoadjuvant treatment was lower in good response group than that of poor response group, with a median TLC of 1.08 and 1.29, respectively (p = 0.011). In the group with neoadjuvant chemotherapy alone, TLC reduction was more obvious in good responder. The median ratio of TLC reduction after neoadjuvant were 39.41% and 33.33% in good and poor responder group, respectively (p = 0.037).

Items Good response group Poor response group
Ratio of TLC reduction of all 307 patients 36.00% ± 3.06% 36.00% ± 2.99% 32.00% ± 2.99% 16.00% ± 5.955
Ratio of TLC reduction in chemotherapy group 27.0% ± 4.16% 9.78% ± 5.16% 11.04% ± 3.58 5.06% ± 6.46%
TLC before neoadjuvant 2.003 ± 0.056 2.041 ± 0.048
TLC after neoadjuvant 1.263 ± 0.044 1.427 ± 0.056


TLC reduction is more apparent in patients with good response after neoadjuvant treatment. The consumption of lymphocytes might indicate the immune response inside tumors after neoadjuvant treatment, which could be a predictor of sensitivity to preoperative therapy.

Clinical trial identification

Legal entity responsible for the study

Yanhong Deng




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings